Home Electrophoretic separations of cerebrospinal fluid proteins in clinical investigations
Article
Licensed
Unlicensed Requires Authentication

Electrophoretic separations of cerebrospinal fluid proteins in clinical investigations

  • Simona D'Aguanno , Piero Del Boccio , Sergio Bernardini , Enzo Ballone , Carmine Di Ilio , Giorgio Federici and Andrea Urbani
Published/Copyright: April 1, 2007
Become an author with De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 45 Issue 4

Abstract

The cerebrospinal fluid (CSF) is a key sample in the research for novel molecular biomarkers of neurodegenerative disorders. CSF represents a repertoire of neuro-secreted, biosynthesised and metabolised molecular products of the central nervous system (CNS). Diffusion of macromolecules from the peripheral circulatory system to the CSF is highly regulated by the blood-brain barrier, which prevents uncontrolled distribution of proteins in the CNS. The development of reproducible high resolution separations of proteins in 2-D electrophoresis methods by the advent of immobilised pH gradient has opened the route to multivariate holistic protein pattern investigation of CSF into neurodegenerative disorders. Moreover, the introduction of pre-fractionation techniques such as free flow electrophoresis is currently increasing the dynamic depth of proteome analysis. Alzheimer's disease (AD) and other forms of dementia, demyelinating diseases, Parkinson's disease (PD), and Creutzfeldt-Jakob disease (CJD) have been evaluated for biomarker discovery by CSF investigation in multiple studies. However, the statistical design of these clinical cross-sectional investigations remains a limited factor given the strong statistical power required for complex multivariate analysis. These initial evidences are of particular interest in dissecting specific molecular mechanisms. The development of fast and economic profiling of CSF by linear matrix assisted laser desorption ionisation time-of-flight mass spectrometry (MALDI-TOF-MS) is providing a new ancillary technology to assess sample quality and pre-analytical requirements. In the following we take into account all these issues in the CSF proteomics investigation, especially highlighting the possible application in the development of clinical molecular biomarkers.

Clin Chem Lab Med 2007;45:437–49.


Corresponding author: Prof. Andrea Urbani, Laboratorio di Biochimica Analitica e Proteomica, Centro Studi sull'Invecchiamento (Ce.S.I.), Università “G. D'Annunzio” di Chieti e Pescara, Via Colle dell'Ara, 66013 Chieti, Italy Phone: +39-0871-541580, Fax: +39-0871-541598,

Received: 2006-10-10
Accepted: 2007-1-17
Published Online: 2007-04-01
Published in Print: 2007-04-01

©2007 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Electrophoretic separations of cerebrospinal fluid proteins in clinical investigations
  2. Haemophilia A: molecular insights
  3. Quality specifications: self pleasure for clinical laboratories or added value for patient management?
  4. A724A polymorphism of sarco(endo)plasmic reticulum Ca2+-ATPase 2 (SERCA2) in hypertensive patients
  5. Associations of common polymorphisms in the thymidylate synthase, reduced folate carrier and 5-aminoimidazole-4-carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase genes with folate and homocysteine levels and venous thrombosis risk
  6. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 (PPARγ-2) gene is associated with greater insulin sensitivity and decreased risk of type 2 diabetes in an Iranian population
  7. A novel frameshift mutation of the lecithin:cholesterol acyltransferase (LCAT) gene associated with renal failure in familial LCAT deficiency
  8. The c.–292C>T promoter polymorphism increases reticulocyte-type 15-lipoxygenase-1 activity and could be atheroprotective
  9. The genetic polymorphisms of β3-adrenergic receptor (AR) Trp64Arg and β2-AR Gln27Glu are associated with obesity in Chinese male hypertensive patients
  10. Diagnostic performance of combined specific urinary proteins and urinary flow cytometry in urinary tract pathology
  11. Diagnostic accuracy of the FIDIS multiplex fluorescent microsphere immunodetection system for anti-extractable nuclear antigen (ENA) antibodies in connective tissue diseases
  12. Fluorimetric quantitation of citalopram and escitalopram in plasma: developing an express method to monitor compliance in clinical trials
  13. Free serum cortisol: quantification applying equilibrium dialysis or ultrafiltration and an automated immunoassay system
  14. Percutaneous coronary intervention-induced variations in systemic parameters of inflammation: relationship with the mode of stenting
  15. Multicentre physiological reference values for the concentration of creatininium in plasma and diagnostic specificity of glomerular filtration rate estimated with the MDRD equation
  16. Serum levels of ischemia-modified albumin in healthy volunteers after exercise-induced calf-muscle ischemia
  17. Reference intervals for follicle-stimulating hormone, luteinizing hormone and prolactin in children and young adults on the bioMérieux Mini-Vidas system
  18. Limits of usual biochemical alcohol markers in cord blood at term: a fetal/maternal population-based study
  19. Implementing the Stockholm Conference hierarchy of objective quality criteria in a routine laboratory
  20. The diffusion of innovations theory could help laboratorians in research translation
  21. Detection of CYP2D6 polymorphisms *9, *10, and *41 using ARMS-PCR and their allelic frequencies in 400 psychiatric patients
  22. Toward standardization of carbohydrate-deficient transferrin (CDT) measurements: I. Analyte definition and proposal of a candidate reference method
  23. Measurement of free thyroxine in laboratory medicine – proposal of measurand definition
Downloaded on 5.11.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2007.106/html
Scroll to top button